Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep1388 | Thyroid (non-cancer) | ECE2017

Neuroendocrine progression of medullary thyroid cancer – case report

Sepp Krisztian , Besenyi Zsuzsanna , Tiszlavicz Laszlo , Valkusz Zsuzsanna

: Thyroid cancers represent approximately 1% of new cancer diagnoses. Thyroid malignancies are divided into papillary carcinomas (80%), follicular carcinomas (10%), medullary carcinomas (5–10%), anaplastic carcinomas (1–2%) other rare tumours (primary thyroid lymphomas, primary thyroid sarcomas). The main therapeutic options are surgery (mainly total thyreoidectomy), radioiodine treatment (depending on the type and stage of the tumour), levothyroxine therapy (thyroid...

ea0041ep1109 | Thyroid cancer | ECE2016

Screening and follow up of an extended Hungarian family with familial medullary thyroid cancer

Valkusz Zsuzsanna , Sepp Krisztian , Gardi Janos , Patocs Attila

Medullary thyroid carcinoma (MTC) originates from the parafollicular or C cells of the thyroid gland and represents approximately 10% of all thyroid malignancies. The operational classification of FMTC is four or more family members with MTC without objective evidence of pheochromocytoma (PC) and parathyroid hyperplasia. In multiple endocrine neoplasia type 2A (MEN 2A) and familial medullary thyroid cancer (FMTC), the majority of germline mutations are restricted to specific p...

ea0035p567 | Endocrine tumours and neoplasia | ECE2014

Neuroendocrine carcinomas of the thymus: two case reports

Sepp Krisztian , Csajbok Eva , Magony Sandor , Julesz Janos , Valkusz Zsuzsanna

The neuroendocrine tumor of thymus (TNET) is an extremely rare disease. It can occur sporadically or as a part of the multiple endocrine neoplasia (MEN1) syndrome. TNET may secret hormons (ectopic ACTH production). It is a potentially malignant tumor which often develops distant metastases. Its prognostic factors are the tumor size, histological grade, Ki67 index, paraneoplastic symptoms, surgical resection and Masaoka staging. The options for treatment are radical surgery, ch...

ea0022p216 | Clinical case reports and clinical practice | ECE2010

10 years experience with somatostatin analogue (SSA) treatment in multiple endocrin neoplasia type 1 (a case report)

Krisztian Sepp , Zsuzsanna Valkusz , Ildiko Kiss , Laszlo Pavics , Janos Julesz

Multiple endocrine neoplasia (MEN-1) is a rare congenital disease with genetic background. The MEN-1 gene encodes the menin protein, which acts as a tumour suppressor. Mutation of one allele and the inactivation of the other allele of this gene lead to clonal proliferation and to the development of tumours. The clinical manifestation of MEN-1 is a combination of endocrine (most commonly parathyreoid adenomas, entero-pancreatic endocrine tumours, pituitary tumours) and non-endo...

ea0090ep659 | Environmental Endocrinology | ECE2023

Are sugar substitutes potential endocrine disruptors?

Sepp Krisztian , Zsolt Molnar , Peter Hausinger , Miklos Mozes , Radacs Marianna , Valkusz Zsuzsanna , Galfi Marta

Keywords: sugar substitute agent exposures, nutritional biology, neuroendocrine system, oxytocinHuman homeostasis is maintained by the complex functioning of the psycho-neuroendocrine-immune system. If a disturbance is generated in this neuroendocrine system for any reason, it can trigger pathogenic processes. One of the factors disturbing homeostasis today may be changes in dietary habits, e.g. through the use of undue sweeteners (e.g. stevia, xylitol e...

ea0049ep742 | Endocrine Disruptors | ECE2017

The effects of halogenated-hydrocarbon uron herbicides, as endocrine disruptor compounds on the oxytocin (OT) hormone regulation in vitro

Sepp Krisztian , Valkusz Zsuzsanna , Molnar Zsolt , Laszlo Anna , Alapi Tunde , Radacs Marianna , Galfi Marta

The biological organisms are complex systems regulated by the homeostatic back-end network. In these days the growing environmental loads (from industry, household, etc.) contain chemical exposure eg. halogenated hydrocarbons (monuron: MU (C9H11ClN2O), diuron: DU (C9H10Cl2N2O)), which can be endocrine disruptor compounds (EDCs). Synthesis, release of hormones and cell processes of endocrine cells, and...

ea0041ep587 | Endocrine Disruptors | ECE2016

The effects of endocrine disruptors on the in vitroAVP hormone regulation

Sepp Krisztian , Valkusz Zsuzsanna , Molnar Zsolt , Budai I , Alapi Tunde , Radacs Marianna , Galfi Marta

Introduction: Endocrine disruptor compounds (EDCs) are chemicals that may interfere with the endocrine system and produce adverse developmental, reproductive, neurological and immune effects.These agents can be found in household, in the industry and in our environment.Endocrine disruptors are substances that interfere with the synthesis, secretion, transport, binding, action, or elimination of natural hormones in the body that are responsible for development, behavio...

ea0037ep151 | Reproduction, endocrine disruptors and signalling | ECE2015

The effects of endocrine disruptors on the in vitro hormone regulation of rat pituitary

Valkusz Zsuzsanna , Radacs Marianna , Palfoldi Regina , Molnar Zoltan , Sepp Krisztian , Laszlo Anna , Alapi Tamas , Galfi Marta

Endocrine disruptor compounds (EDCs) may cause disorders and alter the normal hormone synthesis and/or release.Aim was to investigate the effects of EDCs on normal hypophysis regulation; particularly the arginine–vasopressine (AVP) activated ACTH release from adenohypophysis cells and the monoamine activated AVP release from neurohypophysis cells.Primary monolayer cell cultures prepared from Wistar rat hypophyses. Separated ad...

ea0037ep884 | Thyroid cancer | ECE2015

Simultaneous occurrence of medullary and papillary thyroid microcarcinomas: case report

Sepp Krisztian , Csajbok Eva , Magony Sandor , Tiszlavicz Laszlo , Tobias Balint , Patocs Attila , Valkusz Zsuzsanna

Thyroid cancers represent ~1% of new cancer diagnoses. Thyroid malignancies are divided into papillary carcinomas (80%), follicular carcinomas (10%), medullary carcinomas (5–10%), anaplastic carcinomas (1–2%), and other rare tumours (primary thyroid lymphomas and primary thyroid sarcomas). The main therapeutic options are surgery (mainly total thyreoidectomy), radioiodine treatment, levothyroxine therapy (TSH suppression dose), others (external beam irradiation, chem...

ea0035p645 | Female reproduction | ECE2014

How to estimate insulin resistance in PCOS patients: HOMA-IR or QUICKI?

Csajbok Eva , Gyoi Alexandra , Katona Renata , Magony Sandor , Sepp Krisztian , Valkusz Zsuzsanna

Insulin resistance affects 50–70% of women with polycystic ovary syndrome (PCOS).The aim of our study was to estimate the prevalence of insulin resistance by different methods in a single cohort of 63 PCOS patients diagnosed by the Rotterdam criteria.Methods: Anthropometric measurement, examination and fasting blood tests were made on the 3–5th days of their periods. HOMA-IR (cut off >2.5) and QUICKI (cut off <0.3...